Tango Therapeutics (TNGX) Investor Presentations - Slideshow

therapeutics" Corporate Overview April 2023 Disclaimer and Safe Harbor Statement | 2 케어 TANGO Tango summary First clinical trial ongoing and three IND filings planned for 2023 • TNG462 phase 1/2 trial initiation expected mid-2023 - a next generation MTA-cooperative PRMT5 inhibitor | --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | Targeting tumor suppressor loss | | | | | | to unmask vulnerabilities in cancer | | | | | | for the n ...